Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
NCT06084286
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
29
Enrollment
OTHER
Sponsor class
Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL:
Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
Sponsor
Sichuan University